Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.73 |
| ▸ | MAOA | P21397 | 2/20 | 0.73 |
| ▸ | MAOB | P27338 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15817186 | 1.00 | MAPK1 (0.73) | MAPK1MAOAMAOBMAPTGAA | |
| SCHEMBL15817187 | 1.00 | MAPK1 (0.73) | MAPK1MAOAMAOBMAPTGAA | |
| SCHEMBL15816657 | 0.89 | MAPK1 (0.74) | MAPK1MAOAMAOBMAPTGAA | |
| SCHEMBL15816659 | 0.89 | MAPK1 (0.74) | MAPK1MAOAMAOBMAPTGAA | |
| SCHEMBL15816660 | 0.89 | MAPK1 (0.74) | MAPK1MAOAMAOBMAPTGAA | |
| SCHEMBL15816945 | 0.89 | MAPK1 (0.67) | MAPK1MAOAMAOBMAPTGAA | |
| SCHEMBL15816946 | 0.89 | MAPK1 (0.67) | MAPK1MAOAMAOBMAPTGAA | |
| SCHEMBL15816944 | 0.89 | MAPK1 (0.67) | MAPK1MAOAMAOBMAPTGAA | |
| SCHEMBL15818349 | 0.88 | MAPK1 (0.83) | MAPK1MAOAMAOBMAPTRAB9A | |
| SCHEMBL15818347 | 0.88 | MAPK1 (0.83) | MAPK1MAOAMAOBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115122-B2 | Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | MAPK1, MAP3K1, MAP3K20 | MAPK1 1/4885MAOA 4054/4885MAOB 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.